🇺🇸 NBIX — Neurocrine Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

164,63 USD

Máx. histórico

185,50

99 días

Caída desde máximo

-11,25%

Rango 52 semanas

122,14 – 186,12

Variación hoy

+3,05%

Cierre anterior

159,76

Rango de hoy

158,66 – 165,86

Volumen hoy

1.507.456

Peor caída histórica

-97,21%

15/03/2006 → 12/11/2009

Recuperado en 2911 días

Volatilidad anualizada ⓘ

61,30%

Información
Nombre completo
Neurocrine Biosciences, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Drug Manufacturers - Specialty & Generic
Empleados
2.500
PER ⓘ
24,43 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
207,50 USD (puede no estar actualizado)
Primera cotización
23/05/1996
Precio actualizado
hace 21 horas
Sobre la empresa

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
18/01/2002 48,55 48,56 43,53 44,53 -6,39% 10,36% 1.646.400
17/01/2002 47,20 48,60 43,40 47,57 +0,66% 11,02% 1.565.900
16/01/2002 46,66 47,67 45,85 47,26 +0,55% 3,90% 764.200
15/01/2002 48,45 48,60 45,90 47,00 -3,69% 5,57% 1.062.800
14/01/2002 51,11 51,11 48,63 48,80 -4,13% 4,85% 507.700
11/01/2002 50,80 52,21 49,91 50,90 +1,15% 4,53% 373.700
10/01/2002 48,66 50,65 48,10 50,32 +3,24% 5,24% 370.200
09/01/2002 50,61 51,40 48,42 48,74 -3,56% 5,89% 404.400
08/01/2002 48,00 51,01 46,70 50,54 +4,83% 8,98% 643.900
07/01/2002 49,77 50,63 48,00 48,21 -4,25% 5,28% 480.900
04/01/2002 51,35 51,45 47,60 50,35 -1,76% 7,50% 1.206.400
03/01/2002 50,66 51,60 50,40 51,25 +1,34% 2,37% 517.600
02/01/2002 51,44 51,50 47,79 50,57 -1,44% 7,21% 688.600
31/12/2001 53,00 53,30 51,00 51,31 -3,21% 4,34% 532.700
28/12/2001 52,40 54,26 52,40 53,01 +0,63% 3,55% 328.800
27/12/2001 53,38 53,50 52,18 52,68 -1,33% 2,47% 325.900
26/12/2001 53,69 54,23 52,66 53,39 -0,13% 2,92% 370.700
24/12/2001 52,99 54,06 52,55 53,46 +0,87% 2,85% 254.400
21/12/2001 50,02 53,03 50,00 53,00 +6,02% 6,06% 612.000
20/12/2001 51,60 51,60 49,30 49,99 -3,21% 4,46% 440.400
19/12/2001 52,30 52,30 50,30 51,65 -1,53% 3,82% 845.500
18/12/2001 52,34 53,23 51,31 52,45 -0,72% 3,67% 708.700
17/12/2001 49,61 52,83 49,50 52,83 +6,62% 6,71% 1.135.100
14/12/2001 46,56 50,07 46,56 49,55 +7,60% 7,54% 1.628.500
13/12/2001 46,04 47,25 44,30 46,05 -0,07% 6,41% 961.000
12/12/2001 49,09 49,09 45,79 46,08 -5,92% 6,72% 1.288.300
11/12/2001 47,36 49,05 47,20 48,98 +3,01% 3,91% 741.600
10/12/2001 49,26 49,49 47,29 47,55 -3,67% 4,47% 821.800
07/12/2001 50,44 50,44 49,06 49,36 -2,06% 2,74% 572.900
06/12/2001 49,15 50,49 48,55 50,40 +1,43% 3,95% 742.400